Anavex Life Sciences (AVXL) - News Mentions

Sign up to add (AVXL) to your portfolio and access more historical data.

0 100%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 0 0%
Gilead Sciences
Gilead Sciences
GILD		 0 100%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 1 0%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 0%
BridgeBio Pharma
BridgeBio Pharma
BBIO		 1 0%
BNP Paribas Financial Markets Has $86,000 Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL)
December 19
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
December 16
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
December 9
Intech Investment Management LLC Buys New Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL)
December 8
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
December 1
Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at D. Boral Capital
November 27
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's disease to EMA
November 26
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
November 25
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal
November 25
Atria Investments Inc Takes Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)
November 25
Critical Analysis: Palisade Bio (NASDAQ:PALI) vs. Anavex Life Sciences (NASDAQ:AVXL)
November 16
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario
November 5
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by China Universal Asset Management Co. Ltd.
November 1
Anavex Life Sciences : Phase IIb/III Trial of Blarcamesine in Early Alzheimer Disease Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation
October 30
Anavex Life Sciences’ Promising Alzheimer’s Drug: Buy Rating Justified by Positive Clinical Outcomes and Strategic Advantages
October 30
The Manufacturers Life Insurance Company Raises Stock Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)
October 20

Month over Month

Est. daily news mentions.

Nov 2024 0
Oct 2024 0
Sep 2024 0
Aug 2024 0
Jul 2024 0

How often is Anavex Life Sciences mentioned in the news?

Anavex Life Sciences was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Anavex Life Sciences performing compared to its industry peers?

Anavex Life Sciences underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of Anavex Life Sciences in the last month?

There has been no significant change in the number of news mentions for Anavex Life Sciences' compared to the last month.

Why is it important to track news mentions for Anavex Life Sciences?

By monitoring mentions in the news for Anavex Life Sciences, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Anavex Life Sciences, ultimately improving their investment strategies.

Sign up and get more insights on Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact